Investor List:

Top Diagnostics Series B Investors (190)

Know someone who's actively diligencing and investing? Add them to this list.
About this list
We’ve compiled a list of the top Diagnostics investors. The goal is to help Founders find the best investors to target and get introduced to.
Photo of Geoffrey Smith, Managing Partner at Digitalis Ventures
Geoffrey Smith
Digitalis Ventures·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York (NY), Investors in Los Angeles (CA), Investors in San Francisco (CA), Investors in Boston (MA)
Investors in Therapeutics (Seed), Investors in Diagnostics (Seed), Investors in Diagnostics (Seed), Investors in Therapeutics (Seed), Investors in Diagnostics (Seed), Investors in Therapeutics (Seed), Investors in Diagnostics (Seed), Investors in Diagnostics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Manufacturing (Seed), Investors in Manufacturing (Seed), Investors in Digital Health (Seed), Investors in Manufacturing (Seed), Investors in BioTech (Seed), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Manufacturing (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Manufacturing (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Digital Health (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Diagnostics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Manufacturing (Series A), Investors in BioTech (Series A), Investors in Manufacturing (Series A), Investors in Digital Health (Series A), Investors in Digital Health (Series A), Investors in Manufacturing (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Series A), Investors in Manufacturing (Series A), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in Digital Health (Series A), Investors in Manufacturing (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Digital Health (Series A), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in Diagnostics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Manufacturing (Series B), Investors in Manufacturing (Series B), Investors in BioTech (Series B), Investors in Manufacturing (Series B), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Manufacturing (Series B), Investors in Health & Hospital Services (Series B), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Digital Health (Series B), Investors in Manufacturing (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in Los Angeles / Southern California (Other Lists), Investors in Boston / New England (Other Lists), Investors in New York City (Other Lists), Investors in San Francisco Bay Area (Other Lists)
Photo of James C. Murray, Partner at ExSight Capital Management
James C. Murray
Sweet spot: $1M
Range: $200K - $4.0M
Investors in Europe, Investors in Canada, Investors in United States
Investors in Medical Devices (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Drug Delivery (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Diagnostics (Pre-seed), Investors in Diagnostics (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Hardware (Pre-seed), Investors in Robotics (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Drug Delivery (Pre-seed), Investors in BioTech (Pre-seed), Investors in Medical Devices (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Hardware (Pre-seed), Investors in Robotics (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in BioTech (Pre-seed), Investors in Diagnostics (Seed), Investors in Therapeutics (Seed), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in Drug Delivery (Seed), Investors in Digital Health (Seed), Investors in Diagnostics (Seed), Investors in Health & Hospital Services (Seed), Investors in Therapeutics (Seed), Investors in Hardware (Seed), Investors in Robotics (Seed), Investors in Drug Delivery (Seed), Investors in BioTech (Seed), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in Hardware (Seed), Investors in Robotics (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Pharmaceuticals (Series A), Investors in Drug Delivery (Series A), Investors in Diagnostics (Series A), Investors in Hardware (Series A), Investors in Medical Devices (Series A), Investors in Digital Health (Series A), Investors in Therapeutics (Series A), Investors in Diagnostics (Series A), Investors in Robotics (Series A), Investors in Health & Hospital Services (Series A), Investors in Therapeutics (Series A), Investors in BioTech (Series A), Investors in Drug Delivery (Series A), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series A), Investors in Hardware (Series A), Investors in Robotics (Series A), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Therapeutics (Series B), Investors in Hardware (Series B), Investors in Medical Devices (Series B), Investors in Pharmaceuticals (Series B), Investors in Drug Delivery (Series B), Investors in Diagnostics (Series B), Investors in Digital Health (Series B), Investors in Health & Hospital Services (Series B), Investors in Diagnostics (Series B), Investors in BioTech (Series B), Investors in Robotics (Series B), Investors in Therapeutics (Series B), Investors in Drug Delivery (Series B), Investors in Medical Devices (Series B), Investors in Pharmaceuticals (Series B), Investors in Hardware (Series B), Investors in Robotics (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Canada (Other Lists), Investors in Investors who were founders (Other Lists), Investors in Investors who invested in female founders (Other Lists), Investors in Investors who invested in diverse founders (Other Lists), Investors in New York City (Other Lists)
Photo of Megan Kotrappa, Investor at B Capital Group
Megan Kotrappa
B Capital Group·Investor
Sweet spot: $25.0M
Range: $25.0M - $60.0M
Investors in San Francisco (CA)
Photo of Jason G., Investor at B Capital Group
Jason G.
B Capital Group·Investor
Sweet spot: $25.0M
Range: $25.0M - $60.0M
Investors in SF Bay Area (CA)
Photo of Ling Wong, Managing Partner at Highbury Group
Ling Wong
Highbury Group·Managing Partner
Sweet spot: $10.0M
Range: $500K - $50.0M
Investors in San Francisco (CA), Investors in Seattle (WA)
Investors in Diagnostics (Seed), Investors in Pharmaceuticals (Seed), Investors in Digital Health (Seed), Investors in Diagnostics (Seed), Investors in ClimateTech/CleanTech (Seed), Investors in Generative Tech/AI (Seed), Investors in BioTech (Seed), Investors in Diagnostics (Seed), Investors in Health & Hospital Services (Seed), Investors in Consumer Health (Seed), Investors in Health IT (Seed), Investors in Pharmaceuticals (Seed), Investors in AI (Seed), Investors in Generative Tech/AI (Seed), Investors in Pharmaceuticals (Seed), Investors in Generative Tech/AI (Seed), Investors in Digital Health (Seed), Investors in Consumer Health (Seed), Investors in ClimateTech/CleanTech (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Digital Health (Seed), Investors in Consumer Health (Seed), Investors in Health IT (Seed), Investors in ClimateTech/CleanTech (Seed), Investors in BioTech (Seed), Investors in AI (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in AI (Seed), Investors in Diagnostics (Series A), Investors in Pharmaceuticals (Series A), Investors in ClimateTech/CleanTech (Series A), Investors in Diagnostics (Series A), Investors in Digital Health (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Series A), Investors in Diagnostics (Series A), Investors in Generative Tech/AI (Series A), Investors in Health IT (Series A), Investors in Consumer Health (Series A), Investors in AI (Series A), Investors in Pharmaceuticals (Series A), Investors in Generative Tech/AI (Series A), Investors in Generative Tech/AI (Series A), Investors in Pharmaceuticals (Series A), Investors in Digital Health (Series A), Investors in ClimateTech/CleanTech (Series A), Investors in Consumer Health (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Digital Health (Series A), Investors in Consumer Health (Series A), Investors in Health IT (Series A), Investors in ClimateTech/CleanTech (Series A), Investors in BioTech (Series A), Investors in AI (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in AI (Series A), Investors in Pharmaceuticals (Series B), Investors in Diagnostics (Series B), Investors in BioTech (Series B), Investors in ClimateTech/CleanTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Digital Health (Series B), Investors in Diagnostics (Series B), Investors in Health IT (Series B), Investors in Diagnostics (Series B), Investors in Generative Tech/AI (Series B), Investors in Consumer Health (Series B), Investors in AI (Series B), Investors in Pharmaceuticals (Series B), Investors in Generative Tech/AI (Series B), Investors in Generative Tech/AI (Series B), Investors in Pharmaceuticals (Series B), Investors in ClimateTech/CleanTech (Series B), Investors in Consumer Health (Series B), Investors in Digital Health (Series B), Investors in Consumer Health (Series B), Investors in BioTech (Series B), Investors in ClimateTech/CleanTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Digital Health (Series B), Investors in Health IT (Series B), Investors in BioTech (Series B), Investors in AI (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in AI (Series B), Investors in Seattle / Portland (Other Lists), Investors in Investors who were founders (Other Lists), Investors in San Francisco Bay Area (Other Lists)
Photo of Jenny Rooke, Managing Director at Genoa Ventures
Jenny Rooke
Genoa Ventures·Managing Director
Sweet spot: $2.0M
Range: $250K - $10.0M
Investors in San Francisco (CA)
Investors in Diagnostics (Seed), Investors in Diagnostics (Seed), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series B), Investors in BioTech (Series B), Investors in BioTech (Series B), Investors in San Francisco Bay Area (Other Lists)
Photo of George C. Petrocheilos, Managing Partner at Catalio Capital
George C. Petrocheilos
Catalio Capital·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Baltimore (MD), Investors in Athens (Greece), Investors in New York (NY)
Investors in Diagnostics (Seed), Investors in Drug Delivery (Seed), Investors in Drug Delivery (Seed), Investors in Cybersecurity (Seed), Investors in Diagnostics (Seed), Investors in Medical Devices (Seed), Investors in Drug Delivery (Seed), Investors in Robotics (Seed), Investors in BioTech (Seed), Investors in Cybersecurity (Seed), Investors in Diagnostics (Seed), Investors in Medical Devices (Seed), Investors in Robotics (Seed), Investors in BioTech (Seed), Investors in Medical Devices (Seed), Investors in Cybersecurity (Seed), Investors in Robotics (Seed), Investors in BioTech (Seed), Investors in Drug Delivery (Series A), Investors in Diagnostics (Series A), Investors in Drug Delivery (Series A), Investors in Cybersecurity (Series A), Investors in Drug Delivery (Series A), Investors in Medical Devices (Series A), Investors in Diagnostics (Series A), Investors in Robotics (Series A), Investors in BioTech (Series A), Investors in Medical Devices (Series A), Investors in Diagnostics (Series A), Investors in Cybersecurity (Series A), Investors in Robotics (Series A), Investors in BioTech (Series A), Investors in Medical Devices (Series A), Investors in Cybersecurity (Series A), Investors in Robotics (Series A), Investors in BioTech (Series A), Investors in Cybersecurity (Series B), Investors in Drug Delivery (Series B), Investors in Drug Delivery (Series B), Investors in Robotics (Series B), Investors in Drug Delivery (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Medical Devices (Series B), Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in Diagnostics (Series B), Investors in Cybersecurity (Series B), Investors in Robotics (Series B), Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in Robotics (Series B), Investors in Cybersecurity (Series B), Investors in BioTech (Series B), Investors in Washington, D.C. (Other Lists), Investors in New York City (Other Lists)
Photo of Leslie Goldman Tepper, General Partner at The Artemis Fund
Leslie Goldman Tepper
The Artemis Fund·General Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Houston (TX)
Investors in Diagnostics (Seed), Investors in Medical Devices (Seed), Investors in Web3/Blockchain (Seed), Investors in Diagnostics (Seed), Investors in E-commerce (Seed), Investors in FinTech (Seed), Investors in Medical Devices (Seed), Investors in Web3/Blockchain (Seed), Investors in E-commerce (Seed), Investors in FinTech (Seed), Investors in Medical Devices (Series B), Investors in Diagnostics (Series B), Investors in Web3/Blockchain (Series B), Investors in E-commerce (Series B), Investors in Diagnostics (Series B), Investors in FinTech (Series B), Investors in Medical Devices (Series B), Investors in Web3/Blockchain (Series B), Investors in E-commerce (Series B), Investors in FinTech (Series B), Investors in Austin (Other Lists)
Get new data & insights delivered to your inbox
Firms investing in this space